Close

Servier to market Intarcia’s type 2 diabetes treatment outside US and Japan

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Tjoapack Expands Injectable Packaging Capabilities Globally

Increased Capabilities in the United States Tjoapack is finishing up...

API China, PHARMCHINA & NHNE 2025 Conclude with Global Win

API China, PHARMCHINA & NHNE 2025 Close in Guangzhou...

Under-Eye Wrinkle Treatment: How to Reduce Puffiness and Fine Lines

As we age, the skin around our eyes begins...

France-based pharmaceutical research company Servier has partnered with Intarcia Therapeutics to develop and commercialise its ITCA 650, outside the US and Japan.

ITCA 650 is Intarcia’s investigational therapy for the treatment of type 2 diabetes. The company is currently carrying out a Phase III clinical trial programme, Freedom, for ITCA 650.

As part of the deal, Intarcia will receive an upfront payment and total potential development, regulatory and sales milestone payments of $1bn.

Intarcia Therapeutics president Kurt Graves said: “As one of the largest ex-US partnering deals ever in the biotechnology industry, our collaboration with Servier is yet another major milestone in a series of significant achievements over the last few years that are truly transformational for Intarcia and our stakeholders.”

The payments will include $401m near-term with an upfront payment of $171m and three early stage regulatory milestones of $230m, as well as $650m in additional development, regulatory and sales milestones.

In addition, Intarcia will receive ex-US/Japan tiered sales-related payments.

The ITCA 650 will include Intarcia’s technology platform, involving a matchstick-size, miniature osmotic pump that is placed sub-dermally to offer continuous and consistent drug therapy.

It also features the firm’s formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for extended periods of time.

Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist, marketed worldwide as twice-daily and once-weekly self-injection therapies for type 2 diabetes.

ITCA 650 will be the first injection-free GLP-1 therapy that can deliver up to a full year of treatment from a single placement, once it receives approval.

Latest stories

Related stories

Tjoapack Expands Injectable Packaging Capabilities Globally

Increased Capabilities in the United States Tjoapack is finishing up...

API China, PHARMCHINA & NHNE 2025 Conclude with Global Win

API China, PHARMCHINA & NHNE 2025 Close in Guangzhou...

Under-Eye Wrinkle Treatment: How to Reduce Puffiness and Fine Lines

As we age, the skin around our eyes begins...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back